Literature DB >> 32734414

Determining whether postoperative chemoradiotherapy is required in patients with pathologic T3N0 rectal cancer with negative resection margin.

Jong Yun Baek1, Jeong Il Yu2, Hee Chul Park3, Doo Ho Choi1, Gyu Sang Yoo1, Woo Yong Lee4, Seong Hyeon Yun4, Yong Beom Cho4, Yoon Ah Park4, Hee Cheol Kim4, Heerim Nam5.   

Abstract

PURPOSE: This study aimed to identify the risk factors for locoregional recurrence (LR) and determine possible candidates for postoperative concurrent chemoradiotherapy (CCRT) in pathologic T3N0 (pT3N0) rectal cancer patients with a negative resection margin after total mesorectal excision (TME).
METHOD: Data from 365 patients who had pT3N0 rectal cancer between 2003 and 2012 in the Samsung Medical Center were reviewed. All patients underwent upfront surgery without preoperative treatment. Postoperative management involved either no adjuvant therapy (n = 122), chemotherapy alone (n = 100), or CCRT (n = 143).
RESULTS: The median follow-up duration was 71 months. The 5-year overall survival, disease-free survival, and LR-free survival (LRFS) rates were 95.9%, 86.9%, and 96.3%, respectively. When comparing the three groups (surgery alone [n = 122], chemotherapy alone [n = 100], and CCRT [n = 143]), there was no significant difference in LRFS among them (94.0%, 93.4%, and 99.2%, respectively; p = 0.20). However, when patients were stratified by risk factors (distance from anal verge ≤ 5 cm and distal resection margin [DRM] ≤ 2 cm), the 5-year LRFS improved by more than 10% by adding CCRT (98.9% with CCRT vs. 87.4% without CCRT, p = 0.006) in those with more than one risk factor. Postoperative CCRT did not affect the 5-year LRFS (100% with CCRT vs. 99.0% without CCRT, p = 0.66) in patients with no risk factors.
CONCLUSION: Postoperative CCRT significantly decreased LR in patients with pT3N0 rectal cancer with a negative resection margin but having a distance from the anal verge ≤ 5 cm or DRM ≤ 2 cm.

Entities:  

Keywords:  Local; Radiotherapy; Rectal neoplasm; Recurrence; Risk factors

Mesh:

Year:  2020        PMID: 32734414     DOI: 10.1007/s00384-020-03701-z

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  2 in total

1.  A nomogram for predicting 10-year cancer specific survival in patients with pathological T3N0M0 rectal cancer.

Authors:  Shuang Liu; Shanfei Yang; Haina Yu; Huilong Luo; Gong Chen; Yuanhong Gao; Rui Sun; Weiwei Xiao
Journal:  Front Med (Lausanne)       Date:  2022-08-22

2.  Effectiveness of radiotherapy for local control in T3N0 rectal cancer managed with total mesorectal excision: a meta-analysis.

Authors:  Michael Jonathan Kucharczyk; Andrew Bang; Michael C Tjong; Stefania Papatheodorou; Jesus C Fabregas
Journal:  Oncotarget       Date:  2022-10-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.